药品价格水平理论与实证分析：以天津市基本医疗保险药品为例-theoretical and empirical analysis of drug price level taking tianjin basic medical insurance drugs as an example.docxVIP

下载本文档

6
0
约4.69万字
约 64页
2018-06-03 发布于上海
举报
版权申诉

药品价格水平理论与实证分析：以天津市基本医疗保险药品为例-theoretical and empirical analysis of drug price level taking tianjin basic medical insurance drugs as an example.docx

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

药品价格水平理论与实证分析：以天津市基本医疗保险药品为例-theoretical and empirical analysis of drug price level taking tianjin basic medical insurance drugs as an example

ABSTRACTOBJECTIVES: To explore the best selection strategies of drug price indices using in China, and to provide precise drug price level of different administrative regulation levels (the essential and non-essential drugs ), and different therapeutic categories (the antimicrobial and antineoplastic drugs).METHODS: Data of 30% random sample of enrollees from 2008-2010 Tianjin Urban Employee Basic Medical Insurance databases was used. Laspeyres, Paasches, Fisher and chained Fisher index methods were employed to measure the price level. Price indices were calculated both at molecule level (defined by active ingredient) and product level (defined by molecule, strength, preparation and manufacturer). Units of quantity and price were defined as per DDD, per milligram of active ingredient, and per minimum unit separately to calculate the indices.RESULTS: (1) From 2008Q1 to 2010Q4, there were 12.4 kinds of the antimicrobial basic medical insurance drugs (BMIDs), 3.2 kinds of the antineoplastic BMIDs, 20.7 kinds of the antimicrobial essential drugs (EDs), 7.3 kinds of the antimicrobial insurance non-essential drugs (INEDs) in per molecule, these indicated that the competition of the antimicrobial BMIDs was larger than the antineoplastic BMIDs, and the competition of the antimicrobial EDs was larger than the antimicrobial INEDs;(2) At the molecule level, 85% of the antimicrobial BMIDs, 77% of the antineoplastic BMIDs, 98% of the antimicrobial EDs, 78% of the antimicrobial INEDs wereconstantly used；At the product level, only 26% of the antimicrobial BMIDs, 39% ofthe antineoplastic BMIDs, 20% of the antimicrobial EDs, 33% of the antimicrobial INEDs were constantly used, it suggested that with the narrower drug definition, the less of drugs were constantly used; (3) The price level of Antimicrobial EDs and INEDs decreased heavily, and the former decreased faster than the latter (43% vs. 16%, Chained Fisher-DDD, at the molecule level); (4) The price level of antim